KR102292206B1 - 티로신 유도체 및 이를 포함하는 조성물 - Google Patents

티로신 유도체 및 이를 포함하는 조성물 Download PDF

Info

Publication number
KR102292206B1
KR102292206B1 KR1020167013133A KR20167013133A KR102292206B1 KR 102292206 B1 KR102292206 B1 KR 102292206B1 KR 1020167013133 A KR1020167013133 A KR 1020167013133A KR 20167013133 A KR20167013133 A KR 20167013133A KR 102292206 B1 KR102292206 B1 KR 102292206B1
Authority
KR
South Korea
Prior art keywords
delete delete
tyrosine
methyl
amino
propanoate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020167013133A
Other languages
English (en)
Korean (ko)
Other versions
KR20160072239A (ko
Inventor
스티븐 호프만
Original Assignee
타임, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 타임, 인크. filed Critical 타임, 인크.
Publication of KR20160072239A publication Critical patent/KR20160072239A/ko
Application granted granted Critical
Publication of KR102292206B1 publication Critical patent/KR102292206B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/02—Radiation therapy using microwaves
    • A61N5/022—Apparatus adapted for a specific treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020167013133A 2013-10-22 2014-10-21 티로신 유도체 및 이를 포함하는 조성물 Expired - Fee Related KR102292206B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361894279P 2013-10-22 2013-10-22
US61/894,279 2013-10-22
US14/062,194 US9585841B2 (en) 2013-10-22 2013-10-24 Tyrosine derivatives and compositions comprising them
US14/062,194 2013-10-24
PCT/US2014/061527 WO2015061288A1 (en) 2013-10-22 2014-10-21 Tyrosine derivatives and compositions comprising them

Publications (2)

Publication Number Publication Date
KR20160072239A KR20160072239A (ko) 2016-06-22
KR102292206B1 true KR102292206B1 (ko) 2021-08-24

Family

ID=52826750

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167013133A Expired - Fee Related KR102292206B1 (ko) 2013-10-22 2014-10-21 티로신 유도체 및 이를 포함하는 조성물

Country Status (23)

Country Link
US (2) US9585841B2 (enExample)
EP (1) EP3060200B1 (enExample)
JP (1) JP6684210B2 (enExample)
KR (1) KR102292206B1 (enExample)
CN (1) CN106232105A (enExample)
AU (1) AU2014340263B2 (enExample)
CA (1) CA2927980C (enExample)
CY (1) CY1124386T1 (enExample)
DK (1) DK3060200T3 (enExample)
ES (1) ES2879947T3 (enExample)
HR (1) HRP20210999T1 (enExample)
HU (1) HUE055110T2 (enExample)
IL (1) IL245173B (enExample)
LT (1) LT3060200T (enExample)
MX (1) MX384083B (enExample)
PH (1) PH12016500729A1 (enExample)
PL (1) PL3060200T3 (enExample)
PT (1) PT3060200T (enExample)
RS (1) RS62216B1 (enExample)
SI (1) SI3060200T1 (enExample)
SM (1) SMT202100437T1 (enExample)
WO (1) WO2015061288A1 (enExample)
ZA (1) ZA201602770B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
US20170333451A1 (en) * 2016-05-18 2017-11-23 Tyme, Inc. Dihydrotestosterone and dihydrotestosterone derivatives and promoters in the treatment of cancer
JP2019537608A (ja) * 2016-11-15 2019-12-26 タイム，インコーポレーテッド 癌の処置のための医薬組成物および方法
EA201991305A1 (ru) * 2016-11-30 2019-10-31 Производные тирозина и композиции, включающие их
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
WO2018195411A1 (en) * 2017-04-21 2018-10-25 Steven Hoffman Compositions and methods for treating retinopathy
BR112020001074A2 (pt) * 2017-07-19 2020-07-14 Hoffman Technologies, Inc. composição
WO2019059634A1 (ko) * 2017-09-19 2019-03-28 주식회사 스킨큐씨 D-타이로신 또는 이를 포함하는 펩타이드를 포함하는 피부 미백용 조성물
RU2719575C1 (ru) * 2019-02-01 2020-04-21 Общество с ограниченной ответственностью "Центр ранней диагностики нейродегенеративных заболеваний (НДЗ)" Фармацевтическая композиция на основе альфа-метил-п-тирозина и способ ранней диагностики болезни Паркинсона
KR20220098682A (ko) * 2019-05-14 2022-07-12 타임, 인크. 암을 치료하기 위한 조성물 및 방법
EP4045027A1 (en) * 2019-10-15 2022-08-24 Tyme, Inc. Alkylesters of alpha-methyl-dl-tyrosine for use in treating cancer
CN115515575A (zh) * 2020-01-17 2022-12-23 迪美公司 用于调节癌症的酪氨酸衍生物
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
WO2023128791A1 (ru) * 2021-12-30 2023-07-06 Общество С Ограниченной Ответственностью "Центр Ранней Диагностики Нейродегенеративных Заболеваний" Комбинированное лекарственное средство для ранней диагностики болезни паркинсона

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020854A1 (en) 1993-03-04 1994-09-15 The Minister Of Agriculture Fisheries And Food In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Selective binding materials and assays
WO2013109610A1 (en) * 2012-01-17 2013-07-25 Steven Hoffman Pharmaceutical compositions and methods

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189604A (en) 1975-07-22 1980-02-19 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Bestatin
CA1108180A (en) 1976-07-21 1981-09-01 Hamao Umezawa Analogs of bestatin
US4165382A (en) 1977-10-17 1979-08-21 Jose Pozuelo Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine
US4117161A (en) 1977-05-16 1978-09-26 Jose Pozuelo Method of pharmacologically treating drug addiction with alpha-methyl-para-tyrosine
US4389415A (en) 1978-01-24 1983-06-21 Merck & Co., Inc. Method of treating hypertension
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
US5683981A (en) 1987-05-22 1997-11-04 Competitive Technologies, Inc. Cyclic bridged analogs of α-MSH and methods thereof
JP2668880B2 (ja) * 1987-06-23 1997-10-27 日本油脂株式会社 被覆アミノ酸類の製造方法
US4806360A (en) * 1987-10-23 1989-02-21 Advanced Polymer Systems Synthetic melanin aggregates
US5073541A (en) 1987-11-18 1991-12-17 Administrators Of The Tulane Educational Fund Treatment of small cell lung cancer with somatostatin analogs
JPH02286602A (ja) * 1989-04-28 1990-11-26 Nippon Tokushu Noyaku Seizo Kk 徐放性農薬粒剤
US5225435A (en) 1990-05-18 1993-07-06 Yale University Soluble melanin
US5310539A (en) * 1991-04-15 1994-05-10 Board Of Regents, The University Of Texas System Melanin-based agents for image enhancement
AU5611694A (en) * 1992-11-19 1994-06-08 Bristol-Myers Squibb Company Compositions and methods for temporarily coloring hair using solubilized melanin
EP0696919B1 (en) 1993-04-05 2002-01-30 Competitive Technologies, Inc. Diagnosis and treatment of erectile dysfunction
US8828432B2 (en) * 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
IT1291633B1 (it) 1997-04-22 1999-01-11 Pharmaconsult S A S Uso dell'alfa-metil-p-tirosina per inibire la produzione di melanina nei melanociti dell'iride
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
IL138214A0 (en) 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
AU775289B2 (en) 1998-08-21 2004-07-29 Children's Medical Center Corporation Use of melanin for inhibition of angiogenesis and macular degeneration
US20060052319A9 (en) * 2000-04-03 2006-03-09 Sudhir Agrawal Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcritpion coupled repair genes
US20030114362A1 (en) 2001-06-08 2003-06-19 Novaspin Biotech Gmbh Penta-or tetrapeptide binding to somatostatin receptors and the use of the same
WO2003059321A1 (en) * 2001-12-21 2003-07-24 Soane David S Use of oligomers and polymers for drug solublization, stabilization, and delivery
US8620406B2 (en) * 2004-01-23 2013-12-31 Boston Scientific Scimed, Inc. Medical devices visible by magnetic resonance imaging
EP1718145A4 (en) * 2004-02-02 2012-03-07 Biosight Ltd CONJUGATES FOR CANCER THERAPY AND DIAGNOSIS
EP1768692B8 (en) * 2004-07-01 2015-06-17 Yale University Targeted and high density drug loaded polymeric materials
ES2327421T3 (es) 2005-03-11 2009-10-29 Gpc Biotech Ag Terapia antiproliferativa combinada que comprende satraplatino o jm118 y docetaxel.
CN101193626A (zh) 2005-03-11 2008-06-04 益德威士医药股份有限公司 奥曲肽的受控释放制剂
EP1907444B1 (en) * 2005-04-01 2009-08-19 Intezyne Technologies Incorporated Polymeric micelles for drug delivery
US8758723B2 (en) * 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
ES2544244T3 (es) 2006-04-19 2015-08-28 The Board Of Regents Of The University Of Texas System Composiciones y métodos para la formación de imágenes celulares y terapia
WO2007129062A1 (en) * 2006-05-08 2007-11-15 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
CN101138634A (zh) * 2006-09-07 2008-03-12 于保法 用于治疗肿瘤的组合物
FR2918990B1 (fr) * 2007-07-20 2012-12-21 Innov Ia Procede de preparation de compositions pulverulentes stables
WO2009054001A1 (en) 2007-10-22 2009-04-30 Biocon Limited A pharmaceutical composition and a process thereof
JP2011513370A (ja) 2008-03-07 2011-04-28 ファルマ・マール・ソシエダード・アノニマ 改善された抗腫瘍治療法
EP2106806A1 (en) * 2008-03-31 2009-10-07 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Nanoparticles for targeted delivery of active agents to the lung
WO2009131631A1 (en) 2008-04-14 2009-10-29 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
KR101078302B1 (ko) * 2008-05-29 2011-10-31 (주)프로넥스 약물전달체
US20110200556A1 (en) 2008-08-20 2011-08-18 The United States Of America, As Represented By Th E Secretary, Department Of Health And Human Servi Chemoprevention of head and neck squamous cell carcinomas
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
ES2685947T3 (es) 2009-04-10 2018-10-15 Haiyan Qi Agentes antienvejecimiento
WO2011112576A1 (en) 2010-03-10 2011-09-15 Ambrilia Biopharma Inc. Microspheres for sustained release of octreotide acetate
EP2593101A4 (en) * 2010-07-18 2014-01-01 Niiki Pharma Inc POLYTHERAPY USING RUTHENIUM COMPLEX
US9724657B2 (en) * 2013-10-22 2017-08-08 Tyme, Inc. High-speed centrifugal mixing devices and methods of use
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020854A1 (en) 1993-03-04 1994-09-15 The Minister Of Agriculture Fisheries And Food In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Selective binding materials and assays
WO2013109610A1 (en) * 2012-01-17 2013-07-25 Steven Hoffman Pharmaceutical compositions and methods

Also Published As

Publication number Publication date
RS62216B1 (sr) 2021-09-30
CA2927980C (en) 2022-07-19
JP6684210B2 (ja) 2020-04-22
WO2015061288A1 (en) 2015-04-30
KR20160072239A (ko) 2016-06-22
CN106232105A (zh) 2016-12-14
US20150112116A1 (en) 2015-04-23
EP3060200B1 (en) 2021-05-26
AU2014340263A1 (en) 2016-05-19
CA2927980A1 (en) 2015-04-30
IL245173A0 (en) 2016-06-30
IL245173B (en) 2020-10-29
MX384083B (es) 2025-03-14
CY1124386T1 (el) 2022-07-22
LT3060200T (lt) 2021-08-25
AU2014340263B2 (en) 2019-11-21
SI3060200T1 (sl) 2021-11-30
NZ719457A (en) 2021-02-26
PH12016500729A1 (en) 2016-05-30
US11058638B2 (en) 2021-07-13
US20170172924A1 (en) 2017-06-22
PL3060200T3 (pl) 2021-10-11
EP3060200A1 (en) 2016-08-31
ES2879947T3 (es) 2021-11-23
HUE055110T2 (hu) 2021-10-28
US9585841B2 (en) 2017-03-07
JP2016534071A (ja) 2016-11-04
SMT202100437T1 (it) 2021-09-14
PT3060200T (pt) 2021-07-07
DK3060200T3 (da) 2021-07-12
HRP20210999T1 (hr) 2021-11-26
ZA201602770B (en) 2017-04-26
MX2016005166A (es) 2016-12-14

Similar Documents

Publication Publication Date Title
KR102292206B1 (ko) 티로신 유도체 및 이를 포함하는 조성물
US20220339126A1 (en) Methods for treating cancer
JP2014517050A5 (enExample)
RU2006109467A (ru) Способы лечения рака с использованием ингибиторов hdac
JP2012500800A (ja) 神経因性疼痛の治療法
JP2016534071A5 (enExample)
JP2023522065A (ja) 医薬組成物
JP2017519034A (ja) 手足症候群及び前記症候群に随伴する症候を治療する方法
EP4322942B1 (en) Combination comprising everolimus and amcenestrant
JP2015506988A (ja) 半減期の短い選択的エストロゲン受容体モジュレーターおよびその使用
NZ719457B2 (en) Tyrosine derivatives and compositions comprising them
JPWO2009001764A1 (ja) 統合失調症の治療または予防剤
Yu et al. Discovery of potent and orally available small molecule inhibitors of the SOS1-KRAS interaction

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240818

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240818